OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Otterson on Targetable Biomarkers in Lung Cancer

March 20th 2020

Gregory A. Otterson, MD, discusses targetable biomarkers in non–small cell lung cancer.

Dr. Hari on Misconceptions Regarding Allogeneic Stem Cell Transplant in Multiple Myeloma

March 19th 2020

Parameswaran Hari, MD, MRCP, discusses misconceptions regarding allogeneic stem cell transplant in multiple myeloma.

Dr. Sholl on Challenges With Using Tissue Biopsy for Biomarker Testing in Lung Cancer

March 19th 2020

Lynette M. Sholl, MD, discusses the challenges faced with the use of tissue biopsy to test for biomarkers in lung cancer.

Dr. Hamdan on the Potential Use of Brentuximab Vedotin/Nivolumab in Hodgkin Lymphoma

March 19th 2020

Ayad Hamdan, MD, hematologist and associate professor of medicine at Moores Cancer Center at the University of California, San Diego, discusses the potential use of nivolumab (Opdivo) and brentuximab vedotin (Adcetris) in patients with advanced-stage classical Hodgkin lymphoma.

Dr. Gomella on the Evolution of AR Inhibitors in Prostate Cancer

March 19th 2020

Leonard G. Gomella, MD, professor, chair of the Department of Urology, and director of the Sidney Kimmel Cancer Center Network, of Thomas Jefferson University Hospital, discusses the evolution of androgen receptor (AR) inhibitors in prostate cancer.

Dr. Gerds on Design and Safety Analysis of a Trial With Luspatercept in Myelofibrosis

March 19th 2020

Aaron Gerds, MD, assistant professor of medicine in the Hematology and Medical Oncology Department at the Cleveland Clinic Taussig Cancer Institute, discusses the design and safety analysis of a phase II trial of luspatercept in patients with myelofibrosis-associated anemia.

Dr. Borgen on Unanswered Questions With COVID-19

March 19th 2020

Patrick I. Borgen, MD, discusses what is currently known about coronavirus 2019 and unanswered questions that still need to be addressed.

Dr. Rizvi on the ECHELON-1 Trial Follow-Up in Hodgkin Lymphoma

March 19th 2020

Syed Rizvi, MD, discusses the 4-year follow-up data from the ECHELON-1 trial in Hodgkin lymphoma.

Dr. Goodman on the Role of PD-1 Inhibitors in T-Cell Lymphomas

March 19th 2020

Aaron Goodman, MD, discusses the role of PD-1 inhibitors in T-cell lymphomas.

Dr. Saint Fleur-Lominy on Emerging Agents in MPNs

March 19th 2020

Shella Saint Fleur-Lominy, MD, PhD, an assistant professor in the Department of Medicine at NYU Langone Health

Dr. Le on Treatment Approaches for Oligometastatic Colorectal Cancer

March 19th 2020

Phat Le, MD, assistant professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment approaches for patients with oligometastatic colorectal cancer (CRC).

Dr. Agarwal on Impact of the TITAN Trial With Apalutamide Plus ADT in mCSPC

March 18th 2020

Neeraj Agarwal, MD, discusses the impact of the TITAN trial in metastatic castration-sensitive prostate cancer.

Dr. Fendler on the Impact of 68Ga-PSMA-11 PET Imaging on Prostate Cancer Management

March 18th 2020

Wolfgang Fendler, MD, discusses the impact of 68Ga-PSMA-11 PET imaging on the clinical management of patients with prostate cancer.

Dr. Graff on the Safety of Checkpoint Inhibition in mCRPC

March 18th 2020

Julie N. Graff, MD, discusses the safety profile of pembrolizumab plus enzalutamide in patients with metastatic castration-resistant prostate cancer.

Dr. Grivas on PARP inhibition in Germline and DNA Damage Repair-Mutated mCRPC

March 18th 2020

Petros Grivas, MD, PhD, discusses PARP inhibition in patients with germline and somatic DNA damage repair-mutated metastatic castration-resistant prostate cancer.

Dr. Campbell on Precautions for Preventing Spread of COVID-19

March 18th 2020

Matthew T. Campbell, MD, MS, shares ways to prevent the spread of coronavirus 2019.

Dr. Cone on Cardiac Toxicity With GnRH Agonists in Prostate Cancer

March 18th 2020

Eugene B. Cone, MD, urologist, Massachusetts General Hospital, discusses the cardiac toxicity associated with gonadotropin-releasing hormone (GnRH) agonists in prostate cancer.

Dr. Miklos on the Results of the ZUMA-2 Trial in MCL

March 18th 2020

David Miklos, MD, discusses the results of the phase II ZUMA-2 trial with KTE-X19 in mantle cell lymphoma.

Dr. Abdul Hay on the Evolving Role of Transplant in ALL

March 18th 2020

Mohammad Maher Abdul Hay, MD, discusses the evolving role of transplant in acute lymphoblastic leukemia.

Dr. Bardia on the Potential Impact of COVID-19 on Immunocompromised Patients

March 18th 2020

Aditya Bardia, MD, MPH, discusses the potential impact of novel coronavirus on immunocompromised patients.